These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 19203897)

  • 21. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.
    Boccia RV; Cosgriff TM; Headley DL; Badarinath S; Dakhil SR
    Clin Colorectal Cancer; 2010 Apr; 9(2):102-7. PubMed ID: 20378504
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.
    Sobrero AF; Maurel J; Fehrenbacher L; Scheithauer W; Abubakr YA; Lutz MP; Vega-Villegas ME; Eng C; Steinhauer EU; Prausova J; Lenz HJ; Borg C; Middleton G; Kröning H; Luppi G; Kisker O; Zubel A; Langer C; Kopit J; Burris HA
    J Clin Oncol; 2008 May; 26(14):2311-9. PubMed ID: 18390971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Infusion reactions to the chimeric EGFR inhibitor cetuximab--change to the fully human anti-EGFR monoclonal antibody panitumumab is safe.
    Resch G; Schaberl-Moser R; Kier P; Kopetzky G; Scheithauer W; Sliwa T; Greil R; Nösslinger T; Mayrbäurl B; Thaler J
    Ann Oncol; 2011 Feb; 22(2):486-7. PubMed ID: 21239398
    [No Abstract]   [Full Text] [Related]  

  • 24. Successful long-term management of a patient with late-stage metastatic colorectal cancer treated with panitumumab.
    Seront E; Marot L; Coche E; Gala JL; Sempoux C; Humblet Y
    Cancer Treat Rev; 2010 Feb; 36 Suppl 1():S11-4. PubMed ID: 20189054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today?
    Peeters M; Price T; Van Laethem JL
    Oncologist; 2009 Jan; 14(1):29-39. PubMed ID: 19144681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience.
    Power DG; Shah MA; Asmis TR; Garcia JJ; Kemeny NE
    Invest New Drugs; 2010 Jun; 28(3):353-60. PubMed ID: 19468688
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effective panitumumab treatment in patients with heavily pre-treated metastatic colorectal cancer: a case series.
    Tzovaras AA; Karagiannis A; Margari C; Barla G; Ardavanis A
    Anticancer Res; 2011 Mar; 31(3):1033-7. PubMed ID: 21498734
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer.
    Spigel DR; Greco FA; Waterhouse D; Shipley D; Lane CM; Vazquez ER; Clark BL; Infante JR; Bendell JC; Burris HA; Hainsworth JD
    Clin Adv Hematol Oncol; 2010 Jul; 8(7):480-5, 498. PubMed ID: 20864916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer.
    Wu M; Rivkin A; Pham T
    Clin Ther; 2008 Jan; 30(1):14-30. PubMed ID: 18343240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retrospective analysis of cetuximab monotherapy for patients with irinotecan-intolerant metastatic colorectal cancer.
    Mizota A; Shitara K; Kondo C; Nomura M; Yokota T; Takahari D; Ura T; Inaba Y; Yamaura H; Sato Y; Kato M; Muro K
    Int J Clin Oncol; 2011 Aug; 16(4):416-20. PubMed ID: 21437572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
    Cartwright T; Kuefler P; Cohn A; Hyman W; Berger M; Richards D; Vukelja S; Nugent JE; Ruxer RL; Boehm KA; Asmar L
    Clin Colorectal Cancer; 2008 Nov; 7(6):390-7. PubMed ID: 19036692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.
    Köhne CH; Lenz HJ
    Oncologist; 2009 May; 14(5):478-88. PubMed ID: 19411318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Monoclonal antibodies therapies for colorectal cancer: cétuximab, panitumumab and bevacizumab].
    Piront P; Van Daele D; Belaiche J; Polus M
    Rev Med Liege; 2009; 64(5-6):274-8. PubMed ID: 19642458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer.
    Ouwerkerk J; Boers-Doets C
    Eur J Oncol Nurs; 2010 Sep; 14(4):337-49. PubMed ID: 20580896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The incidence of infusion reactions associated with monoclonal antibody drugs targeting the epidermal growth factor receptor in metastatic colorectal cancer patients: A systematic literature review and meta-analysis of patient and study characteristics.
    Bylsma LC; Dean R; Lowe K; Sangaré L; Alexander DD; Fryzek JP
    Cancer Med; 2019 Sep; 8(12):5800-5809. PubMed ID: 31376243
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integration of panitumumab into the treatment of colorectal cancer.
    Gravalos C; Cassinello J; García-Alfonso P; Jimeno A
    Crit Rev Oncol Hematol; 2010 Apr; 74(1):16-26. PubMed ID: 19616446
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Irinotecan associated with cetuximab given every 2 weeks versus cetuximab weekly in metastatic colorectal cancer.
    Mrabti H; De la Fouchardiere C; Desseigne F; Dussart S; Negrier S; Errihani H
    J Cancer Res Ther; 2009; 5(4):272-6. PubMed ID: 20160361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Panitumumab: a new frontier of target therapy for the treatment of metastatic colorectal cancer.
    Addeo R; Caraglia M; Cerbone D; Frega N; Cimmino G; Abbruzzese A; Del Prete S
    Expert Rev Anticancer Ther; 2010 Apr; 10(4):499-505. PubMed ID: 20397915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.